Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 CVnCoV (Zorecimeran) vaccine in adults ≥45 years with solid or hematologic malignancies receiving systemic anticancer therapy
2021-001735-10Phase 3Terminated
- Sponsor
- Bayer
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zorecimeran in coronavirus disease 2019 (COVID-19), sponsored by Bayer. Primary endpoint: Safety and reactogenicity of Zorecimeran. Started Jun 2021; status: terminated.
02
Drugs
zorecimeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001735-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001735-10.